San Francisco, United States
Herophilus is a San Francisco based biotechnology startup pioneering neurotherapeutics development with a focus on discovering and developing novel drugs for complex brain diseases and disorders. Founded in 2020, the company's mission is encapsulated in its slogan "Cures, not correlations."
Herophilus stands out by employing AI-driven phenotypic screening to address diseases for which traditional discovery techniques have been least successful. The company industrializes the recent revolution in complex in vitro experimental science, leveraging robotic automation and machine learning to characterize the etiology and expression of disease at molecular, cellular, and tissue levels. This approach provides "deep phenotypes" that are crucial in identifying novel therapeutic targets and drug treatments.
The company has recently received a $16.00M investment in a Seed Round on 05 January 2021. The investors in this round include Luxor Capital, KF Ventures, Kinled Holding, and 515 Ventures. With its innovative approach and strong investor backing, Herophilus is well-positioned to make significant strides in neurotherapeutics and potentially revolutionize the treatment landscape for complex brain diseases and disorders.
